Ulcerative Colitis Survey Results
Links shared publicly online about this topic.
- 1,212total visits
Ulcerative Colitis Survey Results
View full resource at livingwithuc.com
Tags: IBD, Ulcerative Colitis
Most Recently Shared on April 26, 2010 at 2:20 pm By:
Read about the key findings of an ulcerative colitis survey. http://bit.ly/arXegZ
Low-calorie diet may be harmful for bowel disease patients
sciencedaily.com — “In a surprising result, researchers looking at the effects of diet on bowel disease found that mice on a calorie-restricted diet were more likely to die after being infected with an inflammation-causing bacterial pathogen in the colon.” View full resource at sciencedaily.com
Most Recently Shared on March 20, 2012 at 8:22 pm By:
Jane Anderson Healthy Eating Advisor
Low-calorie diet may be harmful for bowel disease patients http://t.co/Q7OAGN4U
Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional Therapy - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI I pivotal Phase 3 trial evaluating vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including TNF? antagonists.” View full resource at finance.yahoo.com
Most Recently Shared on February 20, 2012 at 7:58 pm By:
Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to .... http://t.co/wn0gStPX
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (Pentasa®) in active ulcerative colitis - News Press Release | PharmiWeb.com
pharmiweb.com — “Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (Pentasa®) in active ulcerative colitis - News Press Release | PharmiWeb.com” View full resource at pharmiweb.com
Most Recently Shared on October 24, 2011 at 11:36 am By:
Press Release: Results of a new study1 presented today at the United European Gastroenterology Week (UEGW) congr... http://t.co/wN4ecvwh
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (Pentasa®) in active ulcerative colitis | Business Wire
businesswire.com — “Results of a new study1 presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate that a single daily 4g d” View full resource at businesswire.com
Most Recently Shared on October 23, 2011 at 11:32 pm By:
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (Pentasa®) in ... http://t.co/lA4g8KJn
Medical News: DDW: Oral JAK Inhibitor Hits Snag in Crohn's Disease - in Meeting Coverage, DDW from MedPage Today
medpagetoday.com — “CHICAGO -- Phase II trials of an investigational oral Janus kinase inhibitor called tofacitinib in Crohn's disease and ulcerative colitis yielded mixed results, a researcher reported here, indicating” View full resource at medpagetoday.com
Most Recently Shared on September 15, 2011 at 9:27 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: DDW: Oral JAK Inhibitor Hits Snag in Crohn's Disease - http://t.co/vpLJlrU2 from @medpagetoday #health #medicine
Gastroenterology Article | Ulcerative Colitis
mdlinx.com — “Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis” View full resource at mdlinx.com
Most Recently Shared on August 24, 2011 at 11:36 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and... http://t.co/uwm7rPu #GI
Novel cytokine protects mice from colitis
labspaces.net — “Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition.” View full resource at labspaces.net
Most Recently Shared on August 24, 2011 at 3:00 pm By:
Novel cytokine protects mice from colitis - http://t.co/gnKX4Mu
Novel Cytokine Protects Mice from Colitis
newswise.com — “Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Researchers led by Jesús Rivera-Nieves, MD, of the Inflammatory Bowel Disease Center, Division of Gastroenterology at the UC San Diego School of Medicine, have discovered that expression of a newly identified human cytokine protects mice from colitis.” View full resource at newswise.com
Most Recently Shared on August 23, 2011 at 10:42 pm By:
Inflammatory Bowel Syndrome OW Health
Novel Cytokine Protects Mice from Colitis: Inflammatory bowel disease (IBD), which affects more than 1 million p... http://t.co/Vwf40Bt
Novel Cytokine Protects Mice from Colitis
newswise.com — “Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Researchers led by Jesús Rivera-Nieves, MD, of the Inflammatory Bowel Disease Center, Division of Gastroenterology at the UC San Diego School of Medicine, have discovered that expression of a newly identified human cytokine protects mice from colitis.” View full resource at newswise.com
Most Recently Shared on August 23, 2011 at 8:32 pm By:
newswise Health Communicator and Health News
Novel Cytokine Protects Mice from Colitis: Inflammatory bowel disease (IBD), which affects more than 1 million p... http://t.co/rAos4XP
Gastroenterology Article | Ulcerative Colitis
mdlinx.com — “Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis- additional results from two controlled studies” View full resource at mdlinx.com
Most Recently Shared on August 19, 2011 at 12:41 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ul... http://t.co/Y4N6ciI #GI
Cyclosporin no better than infliximab | Gastroenterology Update
gastroenterologyupdate.com.au — “Cyclosporin is no better than infliximab in patients with steroid-resistant severe acute ulcerative colitis, according to a randomised trial presented at DDW, Chicago.” View full resource at gastroenterologyupdate.com.au
Most Recently Shared on May 13, 2011 at 4:05 am By:
Gastroenterology Upd Gastroenterology and Medical Publisher
World first results show cyclosporin no better than infliximab http://bit.ly/lEY2dC #gastroenterology
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints In Phase III Ulcerative Colitis Study
medicalnewstoday.com — “Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presen” View full resource at medicalnewstoday.com
Most Recently Shared on May 11, 2011 at 7:05 am By:
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints In Phase III Ulcerative Colitis Study http://mnt.to/3VGk #crohns #ibd
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
jnj.com — “Johnson & Johnson news and information regarding our operations, products, leaders, and our charitable giving.” View full resource at jnj.com
Most Recently Shared on May 10, 2011 at 7:22 pm By:
eyeonfda Pharma and Health Lawyer
New Phase 3 Study Results 4 REMICADE® in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis - http://ow.ly/4RvIc
Phase 3 Study of Remicade for Ulcerative Colitis in Pediatric Patients - MPR
empr.com — “Centocor Ortho Biotech announced results from its Phase 3 study of Remicade (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC).” View full resource at empr.com
Most Recently Shared on May 10, 2011 at 3:54 pm By:
MPR News: Phase 3 Study of Remicade for Ulcerative Colitis in Pediatric Patients: Centocor Ortho Biotech announc... http://bit.ly/mK0h6c
Phase 3 Study of Remicade for Ulcerative Colitis in Pediatric Patients - ONA
oncologynurseadvisor.com — “Centocor Ortho Biotech announced results from its Phase 3 study of Remicade (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC).” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 10, 2011 at 3:36 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 Study of Remicade for Ulcerative Colitis in Pediatric Patients http://goo.gl/fb/qYVQj
Advertisement
